Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Colca, Jerry R., McDonald, William G., McCommis, Kyle S., Finck, Brian N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721453/
https://www.ncbi.nlm.nih.gov/pubmed/29404453
http://dx.doi.org/10.1002/hep4.1036
Descripción
Sumario:Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193‐197)

Ejemplares similares